Humacyte (NASDAQ:HUMA) Trading Up 15.7%

Humacyte, Inc. (NASDAQ:HUMA) shares were up 15.7% on Tuesday . The company traded as high as $6.08 and last traded at $6.05. Approximately 1,952,324 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 2,202,734 shares. The stock had previously closed at $5.23.

Analyst Ratings Changes

A number of research analysts have weighed in on HUMA shares. BTIG Research lifted their price target on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, September 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $9.80.

Humacyte Stock Performance

The company has a market cap of $728.79 million, a P/E ratio of -5.62 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The stock’s 50-day moving average price is $6.79 and its 200-day moving average price is $5.63.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Equities analysts anticipate that Humacyte, Inc. will post -1.09 EPS for the current year.

Insider Activity

In related news, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the sale, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the sale, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,084,153 shares of company stock worth $6,869,996. 23.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in shares of Humacyte during the second quarter worth about $28,000. Victory Capital Management Inc. bought a new stake in Humacyte during the 4th quarter worth approximately $29,000. Principal Financial Group Inc. acquired a new position in Humacyte in the 2nd quarter valued at approximately $83,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Humacyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after purchasing an additional 7,897 shares during the period. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte during the second quarter worth $97,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.